Paper Details

  1. Home
  2. Paper Details

One-day famciclovir vs. placebo in patient-initiated episodic treatment of recurrent genital herpes in immunocompetent Black patients.

Author: AbudaluMohamed, GaniMashra, HamedKamal, LeonePeter, MithaEssack, ZhouWenchun

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

While there is no evidence that race affects how genital herpes develops or responds to treatment, clinical trials on recurrent genital herpes (RGH) often include a small number of Black participants, despite high rates of herpes infection in this population.
Paper Details　
Original Abstract of the Article :
There are no known racial differences in genital herpes disease pathogenesis or response to therapy. Despite high herpes simplex virus (HSV) seroprevalence in Black persons, clinical trials investigating the treatment of recurrent genital herpes (RGH) have typically enrolled a small proportion of Bl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1185/03007990903554471

データ提供：米国国立医学図書館（NLM）

The Efficacy of Famciclovir for Recurrent Genital Herpes in Black Patients

This study investigates the effectiveness of famciclovir, an antiviral medication, for treating recurrent genital herpes (RGH) in immunocompetent Black patients. Despite the high prevalence of herpes simplex virus (HSV) infection among Black individuals, clinical trials investigating RGH treatment often include limited representation of Black patients. The study aimed to address this gap by evaluating the efficacy of famciclovir for episodic treatment of RGH in a group of Black patients. The study found that famciclovir was effective in reducing the duration and severity of RGH symptoms, demonstrating its potential as a safe and effective treatment option for Black patients.

Addressing Health Disparities in Herpes Treatment

This study highlights the importance of addressing health disparities in herpes treatment. It underscores the need for increased inclusion of diverse populations in clinical trials to ensure that treatment recommendations are applicable to all individuals. It's like understanding the unique challenges and opportunities presented by different oases in the desert. This research provides a valuable contribution to ensuring equitable access to effective herpes treatment.

Navigating the Challenges of Herpes

Recurrent genital herpes can be a challenging condition, causing discomfort, pain, and psychological distress. This study provides reassuring evidence for the effectiveness of famciclovir as a treatment option for Black patients. It's like finding a reliable source of water in the desert, providing relief and support for those dealing with the challenges of herpes.

Dr. Camel's Conclusion

This study offers valuable insights into the efficacy of famciclovir for treating recurrent genital herpes in Black patients. It underscores the importance of ensuring equitable access to effective treatment options for all individuals, regardless of race or ethnicity. This research is a reminder that addressing health disparities is crucial for creating a more just and equitable healthcare system. It's like building a bridge across the desert, connecting individuals with the resources and support they need to navigate the challenges of herpes and live healthier lives.
Date :
  1. Date Completed 2010-05-20
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

20070143

DOI: Digital Object Identifier

10.1185/03007990903554471

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.